Aclaris Therapeutics Q2 2026 net loss $21.5M; cash $170.6M; ATI-052 data supports quarterly dosing

Aclaris Therapeutics, Inc.

Net loss $21.5M in Q2 2026 vs $15.4M in Q2 2025; revenue $1.6M vs $1.8M.
Cash, equivalents and marketable securities $170.6M at June 30, 2026; subsequent ATM raised $40.2M gross from 7.3M shares.
Phase 1a SAD/MAD data for ATI-052 (anti-TSLP/IL-4Rα bispecific) shows favorable safety and potential for quarterly dosing.
Top line results expected H2 2026 from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, and Phase 2 trial of bosakitug in AD.
Plan to initiate Phase 2b program for ATI-052 and Phase 2b trial of modzatinib in lichen planus in Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.